Clinical Trial Update: AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update for AC-1204 in Alzheimer's disease; study completed with long-term efficacy results and optional open-label extension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AC-1204

Snippet

Sponsor: Cerecin | Conditions: Alzheimer's Disease | Phase 2, Phase 3 | Status: COMPLETED